In summary, dual EZH2-G9A/GLP inhibition with HKMTI-1-005 shows promise as an approach to promoting the efficacy of ATRA-based therapy in non-APL AML and warrants further investigation. Here, EHMT1 is linked to acute myeloid leukemia.